Saturday, February 04, 2017 9:27:57 PM
"This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC. This prospectus covers the primary offering by us of up to an aggregate of $100,000,000 of securities. We may offer and sell any combination of the securities described in this prospectus in one or more offerings."
as you can see, they have done 4 offerings in 2 months. This is what companies do. they led people on, then dilute you over and over again. Think about it, they don't make money. They are in debt and don't make money. They lead investors on with promise of great things in the future and all, but in reality, IDXG doesn't make money, so they sell shares. $100 million bucks of IDXG for sale. It's all legal.
Recent IDXG News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:01:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:33:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:14:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:16:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:05:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/22/2023 08:53:38 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/22/2023 08:20:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 07:47:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 05:27:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2023 09:24:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM